Cargando…

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing

Antiplatelet therapy with P2Y(12) receptor inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor) is a cornerstone of medical therapy after percutaneous coronary interventions. Significant prevalence of high on-treatment platelet reactivity (HTPR) on clopidogrel treatment led to introduction of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ostrowska, Małgorzata, Kubica, Jacek, Adamski, Piotr, Kubica, Aldona, Eyileten, Ceren, Postula, Marek, Toma, Aurel, Hengstenberg, Christian, Siller-Matula, Jolanta M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901499/ https://www.ncbi.nlm.nih.gov/pubmed/31850373 http://dx.doi.org/10.3389/fcvm.2019.00176

Ejemplares similares

MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review
por: Czajka, Pamela, et al.
Publicado: (2021)

Plasma Trimethylamine-N-Oxide Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome
por: Eyileten, Ceren, et al.
Publicado: (2021)

Personalized antiplatelet therapy with P2Y(12) receptor inhibitors: benefits and pitfalls
por: Winter, Max-Paul, et al.
Publicado: (2015)

Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
por: Eyileten, Ceren, et al.
Publicado: (2020)

Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease
por: Gager, Gloria M., et al.
Publicado: (2022)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review
por: Pordzik, Justyna, et al.
Publicado: (2019)

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study
por: Adamski, Piotr, et al.
Publicado: (2017)

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
por: Kubica, Jacek, et al.
Publicado: (2016)

Bioresorbable Vascular Scaffolds—Dead End or Still a Rough Diamond?
por: Jeżewski, Mateusz P., et al.
Publicado: (2019)

Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
por: Gager, Gloria M., et al.
Publicado: (2023)

Platelet reactivity patterns in patients treated with dual antiplatelet therapy
por: Winter, Max‐Paul, et al.
Publicado: (2019)

Pretreatment with P2Y(12) Receptor Inhibitors in Acute Coronary Syndromes—Is the Current Standpoint of ESC Experts Sufficiently Supported?
por: Niezgoda, Piotr, et al.
Publicado: (2023)

ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial
por: Kubica, Aldona, et al.
Publicado: (2021)

Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention
por: Siller-Matula, Jolanta M., et al.
Publicado: (2014)

Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2019)

Editorial: Antithrombotic Treatment in Transcatheter Structural Cardiac Interventions and After Cardiac Device Implantation
por: Siller-Matula, Jolanta M., et al.
Publicado: (2020)

Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study
por: Adamski, Piotr, et al.
Publicado: (2017)

ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors
por: Wicik, Zofia, et al.
Publicado: (2020)

Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study
por: Niezgoda, Piotr, et al.
Publicado: (2022)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

Medication adherence and its determinants in patients after myocardial infarction
por: Pietrzykowski, Łukasz, et al.
Publicado: (2020)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

MicroRNAs as Biomarkers of Systemic Changes in Response to Endurance Exercise—A Comprehensive Review
por: Soplinska, Aleksandra, et al.
Publicado: (2020)

Ticagrelor – toward more efficient platelet inhibition and beyond
por: Kubisa, Michał J, et al.
Publicado: (2018)

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)

IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
por: Kubica, Jacek, et al.
Publicado: (2022)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus
por: Pordzik, Justyna, et al.
Publicado: (2021)

Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial
por: Kubica, Jacek, et al.
Publicado: (2015)

MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics
por: Jakubik, Daniel, et al.
Publicado: (2021)

State of the art: Oral antiplatelet therapy
por: Gurbel, Paul A, et al.
Publicado: (2016)

Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19
por: Eyileten, Ceren, et al.
Publicado: (2022)

Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study
por: Eyileten, Ceren, et al.
Publicado: (2022)

Effects of Multidisciplinary Rehabilitation Program in Patients with Long COVID-19: Post-COVID-19 Rehabilitation (PCR SIRIO 8) Study
por: Ostrowska, Małgorzata, et al.
Publicado: (2023)

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study
por: Kubica, Jacek, et al.
Publicado: (2021)

Genetic determinants of platelet response to clopidogrel
por: Kubica, Aldona, et al.
Publicado: (2011)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice
por: Tubek, Stanisław, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2v959f3smbd3g8apil5kjr6o8i